文献速递前列腺癌

SelectMDx尿液mRNA生物标志物检测在前列腺癌中的临床应用

Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-07-09

本研究纳入2019年5月至2020年12月来自10个欧洲国家的5157例接受SelectMDx检测的男性,评估该检测在常规实践中的使用情况。结果显示40.72%的病例获得阴性SelectMDx结果,检测也被用于PSA<3和>10 ng/mL的预期用途之外人群;各国患者临床参数与验证队列存在差异,导致潜在可避免活检数量不同。

要点

  • 40.72%的病例获得阴性SelectMDx结果。
  • 检测被用于PSA<3和>10 ng/mL的预期用途之外患者。
  • 各国患者年龄、PSA密度、DRE结果与验证队列存在差异。

核心结论

  • 在临床使用中,假设阴性SelectMDx结果导致不进行活检的决定,则潜在减少的活检数量为40.72%。
  • 这一比例高于验证队列,可由患者人群差异解释。

研究设计与样本

  • 研究纳入2019年5月至2020年12月期间接受SelectMDx检测且来自定期开展该检测国家的男性,共5157例,来自10个欧洲国家。
  • 比较不同PSA组、年龄组、国家及验证队列之间的临床参数、尿液RNA评分和检测结果,使用Mann-Whitney U检验、卡方检验、Benjamini-Hochberg法和Kruskal-Wallis检验。

主要发现

  • 40.72%的病例获得阴性SelectMDx结果。
  • 检测也被用于PSA<3和>10 ng/mL的预期用途之外患者。
  • 各国患者人群的临床参数(年龄、PSA密度、DRE结果)与验证队列存在差异,导致使用该检测潜在可节省的活检数量不同。

关键数值与推荐

  • 既往验证显示,使用SelectMDx检测作为选择男性进行前列腺活检的决策工具,可避免53%的不必要活检(活检指示无或GG1前列腺癌)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular biomarker tests are developed as diagnostic tools for prostate cancer (PCa) diagnosis. The SelectMDx (MDxHealth, Nijmegen, The Netherlands) test is a urinary-based biomarker test intended to be used to predict presence of high-grade PCa upon biopsy in men with elevated serum prostate-specific antigen (PSA) levels. Previous validation of the SelectMDx test revealed that 53% of the unnecessary biopsies (biopsies indicating no- or GG1 PCa) could be avoided using the SelectMDx test as a decision-tool to select men for prostate biopsy. The objective of this study is to examine the use of the commercially available SelectMDx test under routine, real-life practice. METHODS: Men that underwent a SelectMDx test between May 2019 and December 2020 and that were originating from countries that perform the SelectMDx test on a regular basis were included in this study, resulting in 5157 cases from 10 European countries. Clinical parameters, urinary RNA scores, and test outcomes were compared between PSA groups, age groups, countries, and the validation cohort (described previously [4]) using the Mann-Whitney U test, Chi-Square test, Benjamini-Hochberg and Kruskal-Wallis tests. RESULTS: 40.72% of the cases received a negative SelectMDx result. The test is also used in patients outside the intended-use population (PSA < 3 and >10 ng/mL). Clinical parameters (age, PSA density, DRE outcome) varied between patient population from individual countries and the validation cohort, resulting in differences in the potential number of saved biopsies using the test. CONCLUSIONS: The potential number of reduced biopsies in clinical use was 40,72% using the SelectMDx test, assuming a negative SelectMDx test resulted in the decision not to biopsy the patient. This is higher compared to the validation cohort, which is explained by differences in patient population.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Visser WCH, de Jong H, Steyaert S, et al. Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer. Prostate Cancer Prostatic Dis. 2022. PMID: 35810263. doi:10.1038/s41391-022-00562-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。